They are called wise who put things in their right order
Thomas Aquinas
This Eighth Edition is dedicated to Dr Leslie H. Sobin MD, a pathologist and previous long term Chair of UICC TNM Prognostic Factor Committee. Les, as he is known to colleagues all over the world, has devoted most of his career to help promote globally unified classifications of disease in particular in pathology and cancer staging. This is the first edition since the fourth that has not benefitted from his direct involvement; however his imprint is found throughout this edition. 2 Some changes had already appeared in the TNM Supplement 3 as proposals. Subsequent support warrants their incorporation into the classification. New proposals for tumours of parathyroid carcinoma, and paraganglionoma will be published in the next edition of the TNM Supplement.
In the seventh edition a new approach was adopted to separate stage groupings from prognostic groupings in which other prognostic factors are added to T, N, and M categories. These new prognostic groupings were presented for oesophagus and prostate. In this eighth edition, the term 'stage' is used when only descriptions of anatomic extent of disease are used and 'prognostic group' for when additional prognostic factors are incorporated.
Changes made between the seventh and eighth editions are indicated by a bar at the left-hand side of the text. To avoid ambiguity, users are encouraged to cite the edition and year of the TNM publication they have used in their list of references.
A TNM homepage with Frequently Asked Questions (FAQs) and a form for submitting questions or comments on the TNM can be found at: http:// www.uicc.org.
The UICC's TNM Prognostic Factors Project has a process for evaluating proposals to change the TNM Classification. This procedure aims at a continuous systematic approach composed of two arms: (1) review formal proposals from investigators and (2) an annual literature search for articles concerning improvements to TNM. The proposals and results of the literature search are evaluated by a UICC panel of experts as well as by the TNM Prognostic Factors committee members. 5 The national TNM Committees participated in this process. More details and a checklist that will facilitate the formulation of proposals can be obtained at www.uicc.org.
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Preface
The Editors have much pleasure in acknowledging the great help received from the members of the TNM Prognostic Factors Project Committee and the National Staging Committees Global Representatives and international organizations listed on pages xvi, all of whom volunteered their time.
We thank Professor Patti Groome and Ms Colleen Webber for supervising and performing the literature watch from its inception until 2015 and 2016, respectively. The eighth edition of the TNM Classification is the result of a number of consultative meetings organized and supported by the UiCC and AJCC secretariats.
This publication was made possible by grants 1U58DP001818 and 1U58DP004965 from the Centers for Disease Control and Prevention (CDC) (USA). its contents are solely the responsibility of the authors and do not necessarily represent the official views of the CDC. The current eighth edition of TNM contains rules of classification and staging that correspond with those appearing in the eighth edition of the AJCC Cancer Staging Manual (2017) . 18 While the aim of the UICC and AJCC is to have identical classifications, small differences exist and are identified as footnotes to the text. Wherever possible, the UICC classification is based on published evidence-based recommendation.
To develop and sustain a classification system acceptable to all requires the closest liaison between national and international organizations. As noted, while the classification is based on published evidence, in areas where high-level evidence is not available it is based on international consensus. The continuing objective of the UICC is to present the classification of anatomical extent of cancer globally.
Note
Introduction development and implementation of clinical practice guidelines, and centralized activities such as recording disease extent in cancer registries for surveillance purposes and planning cancer systems. Recording of stage is essential for the evaluation of outcomes of clinical practice and cancer programmes. However, in order to evaluate the long-term outcomes of populations, it is important for the classification to remain stable. There is therefore a conflict between a classification that is updated to include the most current forms of medical knowledge while also maintaining a classification that facilitating longitudinal studies. The UICC TNM Project aims to address both needs.
International agreement on the classification of cancer by extent of disease provides a method of conveying disease extent to others without ambiguity.
There are many axes of tumour classification: for example, the anatomical site and the clinical and pathological extent of disease, the duration of symptoms or signs, the gender and age of the patient, and the histological type and grade of the tumour. All of these have an influence on the outcome of the disease. Classification by anatomical extent of disease is the one with which the TNM system primarily deals.
The clinician's immediate task when meeting a patient with a new diagnosis of cancer is to make a judgment as to prognosis and a decision as to the most effective course of treatment. This judgment and this decision require, among other things, an objective assessment of the anatomical extent of the disease.
To meet the stated objectives a system of classification is needed: 1. that is applicable to all sites regardless of treatment; and 2. that may be supplemented later by further information that becomes available from histopathology and/or surgery. The TNM system meets these requirements.
The General Rules of the TNM System a,b
5. In the case of multiple primary tumours in one organ, the tumour with the highest T category should be classified and the multiplicity or the number of tumours should be indicated in parenthesis, e.g., T2(m) or T2(5). In simultaneous bilateral primary cancers of paired organs, each tumour should be classified independently. In tumours of the liver, ovary and fallopian tube, multiplicity is a criterion of T classification, and in tumours of the lung multiplicity may be a criterion of the M classification. 6. Definitions of the TNM categories and stage may be telescoped or expanded for clinical or research purposes as long as the basic definitions recommended are not changed. For instance, any T, N, or M can be divided into subgroups.
Notes
Introduction pN -Regional Lymph Nodes pNX Regional lymph nodes cannot be assessed histologically pN0
No regional lymph node metastasis histologically pN1-3 Increasing involvement of regional lymph nodes histologically Notes ▪ Direct extension of the primary tumour into lymph nodes is classified as lymph node metastasis. ▪ Tumour deposits (satellites), i.e., macro-or microscopic nests or nodules, in the lymph drainage area of a primary carcinoma without histological evidence of residual lymph node in the nodule, may represent discontinuous spread, venous invasion (V1/2) or a totally replaced lymph node. If a nodule is considered by the pathologist to be a totally replaced lymph node (generally having a smooth contour), it should be recorded as a positive lymph node, and each such nodule should be counted separately as a lymph node in the final pN determination. ▪ Metastasis in any lymph node other than regional is classified as a distant metastasis. ▪ When size is a criterion for pN classification, measurement is made of the metastasis, not of the entire lymph node. The measurement should be that of the largest dimension of the tumour. ▪ Cases with micrometastasis only, i.e., no metastasis larger than 0.2 cm, can be identified by the addition of '(mi)', e.g., pN1(mi).
Sentinel Lymph Node
The sentinel lymph node is the first lymph node to receive lymphatic drainage from a primary tumour. If it contains metastatic tumour this indicates that other lymph nodes may contain tumour. If it does not contain metastatic tumour, other lymph nodes are not likely to contain tumour. Occasionally, there is more than one sentinel lymph node.
The following designations are applicable when sentinel lymph node assessment is attempted: (p)NX(sn) Sentinel lymph node could not be assessed (p)N0(sn) No sentinel lymph node metastasis (p)N1(sn) Sentinel lymph node metastasis
Isolated Tumour Cells
Isolated tumour cells (ITC) are single tumour cells or small clusters of cells not more than 0.2 mm in greatest extent that can be detected by routine H and E stains or immunohistochemistry. An additional criterion has been
